---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-059069"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T18:43:29.821659+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Entrada Q1 net loss $21.7M; announces second candidate ENTR-701 for DM1; IND on track for Q4 2022

## Summary
- Q1 2022 net loss of $21.7M vs $8.4M YoY; R&D expenses rose to $15.7M from $6.2M.
- Cash, equivalents & marketable securities $263.9M at March 31 (down from $291.1M); runway into H2 2024.
- Announced ENTR-701 as second clinical candidate for myotonic dystrophy type 1 (DM1).
- On track to submit IND for ENTR-601-44 (Duchenne MD, exon 44 skipping) in Q4 2022.
- Preclinical data showed durable exon 44 skipping in NHP biceps for at least 12 weeks after single dose of ENTR-601-44.

## SEC filing metadata
- accession: 0001104659-22-059069
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 9.01, 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000110465922059069/0001104659-22-059069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000110465922059069/tm2215094d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-059069
- JSON: https://secwatch.observer/filing/0001104659-22-059069.json
- Plain text: https://secwatch.observer/filing/0001104659-22-059069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.